Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPACCA: firmonertinib versus osimertinib or afatinib in first-line EGFR PACC-mutant advanced NSCLC
jRCT2021250035Phase 3Recruiting
- Sponsor
- ArriVent BioPharma
- Start
- Dec 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of furmonertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by ArriVent BioPharma. Primary endpoints: Progression-free survival and Confirmed overall response rate. Started Dec 2025; status: recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2021250035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021250035.